Cargando…
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
The ability of tumor cells to avoid immune destruction (immune escape) as well as their acquired resistance to anti-cancer drugs constitute important barriers to the successful management of cancer. Interaction between the Programmed Death Ligand 1 (PD-L1) on the surface of tumor cells with the Prog...
Autores principales: | Black, Madison, Barsoum, Ivraym B., Truesdell, Peter, Cotechini, Tiziana, Macdonald-Goodfellow, Shannyn K., Petroff, Margaret, Siemens, D. Robert, Koti, Madhuri, Craig, Andrew W.B., Graham, Charles H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891140/ https://www.ncbi.nlm.nih.gov/pubmed/26859684 http://dx.doi.org/10.18632/oncotarget.7235 |
Ejemplares similares
-
Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia
por: Cotechini, Tiziana, et al.
Publicado: (2014) -
Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021) -
Inhibition of hypoxia-inducible factor 1α accumulation by glyceryl trinitrate and cyclic guanosine monophosphate
por: Kim, Judy, et al.
Publicado: (2020) -
STING agonist therapy in combination with PD-1 immune
checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous
ovarian cancer
por: Ghaffari, Abdi, et al.
Publicado: (2018) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)